Heading,CUI,Semantic Type,Preferred Name,,,
% Change of Co-administered Drug Pharmacokinetic Parameters (90% CI),C0392747|C0443172|C1705241|C3245499|C1521801|C0013227|C1705911|C1254351|C0439083|C0008107|C3259781|C0439087|C3842582,[ftcn]|[qnco]|[qnco]|[geoa]|[ftcn]|[phsu]|[idcn]|[phsu]|[qnco]|[geoa]|[lbpr]|[qnco]|[fndg],Changing|Changed status|Delta (difference)|Colombia|Having administered|Pharmaceutical Preparations|Pharmacokinetic Parameters Domain|Pharmacologic Substance|>90|Chile|Coagulation Index Measurement|<90|90%,,,
AED Co-administered,C0887457|C3245499|C1521801,"[orch, phsu]|[geoa]|[ftcn]",Cystamine Dihydrochloride|Colombia|Having administered,,,
AED Coadministered,C0887457,"[orch, phsu]",Cystamine Dihydrochloride,,,
AED Concentration,C0887457|C0004268|C0086045|C1446561,"[orch, phsu]|[menp]|[menp]|[qnco]",Cystamine Dihydrochloride|Attention|Mental concentration|Concentration measurement,,,
AEDCo-administered,C1521801,[ftcn],Having administered,,,
AEDConcentration,,,,,,
AED Co - administered,C0887457|C3245499|C1521801,"[orch, phsu]|[geoa]|[ftcn]",Cystamine Dihydrochloride|Colombia|Having administered,,,
AED Coadministered,C0887457,"[orch, phsu]",Cystamine Dihydrochloride,,,
AED Concentration,C0887457|C0004268|C0086045|C1446561,"[orch, phsu]|[menp]|[menp]|[qnco]",Cystamine Dihydrochloride|Attention|Mental concentration|Concentration measurement,,,
AEDCoadministered,,,,,,
AEDConcentration,,,,,,
AUC,C0376690,[qnco],Area Under Curve,,,
AUC ofCoadministeredDrug (95% CI),C0376690|C0008107|C3259781,[qnco]|[geoa]|[lbpr],Area Under Curve|Chile|Coagulation Index Measurement,,,
AUC ofCoadministeredDrug(90% CI),C0376690|C0439083|C0008107|C3259781|C0439087|C3842582,[qnco]|[qnco]|[geoa]|[lbpr]|[qnco]|[fndg],Area Under Curve|>90|Chile|Coagulation Index Measurement|<90|90%,,,
AUC ofDidanosine(90% CI),C0376690|C0439083|C0008107|C3259781|C0439087|C3842582,[qnco]|[qnco]|[geoa]|[lbpr]|[qnco]|[fndg],Area Under Curve|>90|Chile|Coagulation Index Measurement|<90|90%,,,
AUC ofDidanosine(95% CI),C0376690|C0008107|C3259781,[qnco]|[geoa]|[lbpr],Area Under Curve|Chile|Coagulation Index Measurement,,,
AUC ofStavudine(95% CI),C0376690|C0008107|C3259781,[qnco]|[geoa]|[lbpr],Area Under Curve|Chile|Coagulation Index Measurement,,,
AUC ofCoadministered Drug(95% CI),C0376690|C0013227|C1254351|C0008107|C3259781,[qnco]|[phsu]|[phsu]|[geoa]|[lbpr],Area Under Curve|Pharmaceutical Preparations|Pharmacologic Substance|Chile|Coagulation Index Measurement,,,
AUC(0-24h)(ng  h/mL),C0376690|C3842591|C0456696|C1442770|C1533072,[qnco]|[fndg]|[tmco]|[tmco]|[qnco],Area Under Curve|0%|per 24 hours|24 Hours|ng/mL/hr,,,
AUCSS(012h)(Extent of systemic exposure),C0439792|C0205373|C0274281|C0332157,[spco]|[ftcn]|[inpo]|[clna],Extent|Systemic|Injury due to exposure to external cause|Exposure to,,,
AUCss(012h) (Extent of systemic exposure),C0439792|C0205373|C0274281|C0332157,[spco]|[ftcn]|[inpo]|[clna],Extent|Systemic|Injury due to exposure to external cause|Exposure to,,,
AUC,C0376690,[qnco],Area Under Curve,,,
Adjusted Dose,C0456081|C0178602|C0869039|C1114758,[ftcn]|[qnco]|[qnco]|[clna],Adjustment Action|Dosage|Unit dose|Dose number:Number:Point in time:^Patient:Quantitative,,,
Alcohol,C0001962|C0001975,"[orch, phsu]|[orch, phsu]",Ethanol|Alcohols,,,
Alpha-Blocker,C0001641,[phsu],Adrenergic alpha-Antagonists,,,
Analgesics: Methadone*,C0002771|C0025605|C1552533,"[phsu]|[orch, phsu]|[hcro, mnob]",Analgesics|Methadone|Methadone Clinic/Center,,,
Anti-coagulant drugs,C0848112,[topp],on anti-coagulants,,,
"Antiarrhythmics: Amiodarone, disopyramide,lidocaine",C0003195|C0002598|C0012702|C0023660,"[phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]",Anti-Arrhythmia Agents|Amiodarone|Disopyramide|Lidocaine,,,
Antibiotics,C0003232|C0003237|C3540704|C3540705|C3540706|C3540707|C3540708|C3540709|C3540710,[antb]|[antb]|[antb]|[antb]|[antb]|[antb]|[antb]|[antb]|[antb],"Antibiotics|Antibiotics, Antitubercular|Antibiotics for systemic use|Antifungal Antibiotics, Topical|Antibiotic throat preparations|Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE|Antibiotics, Gynecological|antibiotics, intestinal|Antibiotics, ophthalmologic",,,
Antibiotics: Clarithromycin*,C0003232|C0003237|C3540704|C3540705|C3540706|C3540707|C3540708|C3540709|C3540710|C0055856,"[antb]|[antb]|[antb]|[antb]|[antb]|[antb]|[antb]|[antb]|[antb]|[antb, orch]","Antibiotics|Antibiotics, Antitubercular|Antibiotics for systemic use|Antifungal Antibiotics, Topical|Antibiotic throat preparations|Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE|Antibiotics, Gynecological|antibiotics, intestinal|Antibiotics, ophthalmologic|Clarithromycin",,,
Antibiotics,C0003232|C0003237|C3540704|C3540705|C3540706|C3540707|C3540708|C3540709|C3540710,[antb]|[antb]|[antb]|[antb]|[antb]|[antb]|[antb]|[antb]|[antb],"Antibiotics|Antibiotics, Antitubercular|Antibiotics for systemic use|Antifungal Antibiotics, Topical|Antibiotic throat preparations|Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE|Antibiotics, Gynecological|antibiotics, intestinal|Antibiotics, ophthalmologic",,,
Anticoagulants,C0003280,[phsu],Anticoagulants,,,
Anticoagulants (oral) - Coumarin Derivatives - Indandione Derivatives,C0003280|C0442027|C0010207,"[phsu]|[spco]|[orch, phsu]",Anticoagulants|Oral|Coumarins,,,
Anticoagulants (oral)- Coumarin Derivatives- Indandione Derivatives,C0003280|C0442027|C0010207,"[phsu]|[spco]|[orch, phsu]",Anticoagulants|Oral|Coumarins,,,
Anticonvulsants,C0003286,[phsu],Anticonvulsants,,,
Anticonvulsants,C0003286,[phsu],Anticonvulsants,,,
Antiretroviral agents,C0599685,[phsu],Anti-Retroviral Agents,,,
Antiretrovirals,,,,,,
Benzodiazapines,,,,,,
Beta-Blockers,C0001645,[phsu],Adrenergic beta-Antagonists,,,
CLINICAL EFFECT(S),C0205210|C1280500|C2348382|C0237412|C0497591|C1553058|C0565930|C2603362,[qlco]|[qlco]|[qlco]|[prog]|[prog]|[prog]|[qnco]|[clna],"Clinical|Effect|Effect, Appearance|Psychologist - Clinical|Social Worker - Clinical|Neuropsychologist - Clinical|per second|S prime",,,
CLINICAL EFFECT(S),C0205210|C1280500|C2348382|C0237412|C0497591|C1553058|C0565930|C2603362,[qlco]|[qlco]|[qlco]|[prog]|[prog]|[prog]|[qnco]|[clna],"Clinical|Effect|Effect, Appearance|Psychologist - Clinical|Social Worker - Clinical|Neuropsychologist - Clinical|per second|S prime",,,
CONCOMITANT DRUG,C0521115|C0013227|C1254351,[tmco]|[phsu]|[phsu],Simultaneous|Pharmaceutical Preparations|Pharmacologic Substance,,,
Caffeine/Xanthine Derivatives,C0006644|C1718515|C3541953|C3541954,"[orch, phsu]|[bacs, orch]|[orch, phsu]|[orch, phsu]","Caffeine|Xanthine derivatives|Xanthine derivatives, psychostimulants, agents used for ADHD and nootropics|Xanthine derivatives, low-ceiling diuretics",,,
Cardiac Glycosides,C0007158,"[orch, phsu]",Cardiac Glycosides,,,
Central Nervous System (CNS) Depressants,C0007681,[phsu],Central Nervous System Depressants,,,
Classes of Drugs,C0456387|C1705943|C4019422|C0013227|C3687832,[inpr]|[clas]|[hlca]|[phsu]|[topp],Class|Class (taxonomic)|Classes - encounter|Pharmaceutical Preparations|Drugs,,,
ClassesofDrug,,,,,,
ClassesofDrugs,,,,,,
Clinical Comment,C0205210|C0282411|C0947611|C0237412|C0497591|C1553058,[qlco]|[inpr]|[inpr]|[prog]|[prog]|[prog],Clinical|Published Comment|Comment|Psychologist - Clinical|Social Worker - Clinical|Neuropsychologist - Clinical,,,
Clinical Comment,C0205210|C0282411|C0947611|C0237412|C0497591|C1553058,[qlco]|[inpr]|[inpr]|[prog]|[prog]|[prog],Clinical|Published Comment|Comment|Psychologist - Clinical|Social Worker - Clinical|Neuropsychologist - Clinical,,,
Clinical Impact:,C0205210|C1825598|C0237412|C0497591|C1553058,[qlco]|[gngm]|[prog]|[prog]|[prog],Clinical|IMPACT gene|Psychologist - Clinical|Social Worker - Clinical|Neuropsychologist - Clinical,,,
Clinical Implications,C0205210|C0237412|C0497591|C1553058,[qlco]|[prog]|[prog]|[prog],Clinical|Psychologist - Clinical|Social Worker - Clinical|Neuropsychologist - Clinical,,,
Clinical Rationale and Magnitude of Drug Interaction,C0205210|C0392360|C2699007|C0237412|C0497591|C1553058|C0449286|C1704240|C0678798|C0687133,[qlco]|[idcn]|[idcn]|[prog]|[prog]|[prog]|[qnco]|[qnco]|[fndg]|[moft],Clinical|Indication of (contextual qualifier)|Rationale|Psychologist - Clinical|Social Worker - Clinical|Neuropsychologist - Clinical|Degree or extent|Magnitude|Adverse drug interaction|Drug Interactions,,,
Clinical Recommendation,C0205210|C0034866|C0237412|C0497591|C1553058,[qlco]|[idcn]|[prog]|[prog]|[prog],Clinical|Recommendation|Psychologist - Clinical|Social Worker - Clinical|Neuropsychologist - Clinical,,,
ClinicalComment,,,,,,
Cm a x,,,,,,
Cmax,C2347813,[qnco],Cmax,,,
Cmax SS (Peak plasma concentration),C2347813|C2699257|C0032105|C1550098|C0444505|C0683150|C3891295,[qnco]|[mamm]|[bdsu]|[bdsu]|[qnco]|[qnco]|[inpr],"Cmax|SS, Rat Strain|Plasma|Plasma, NOS (not otherwise specified)|Peak level|plasma concentration|Subject Status Domain",,,
Cmax ofCoadministeredDrug (95% CI),C2347813|C0008107|C3259781,[qnco]|[geoa]|[lbpr],Cmax|Chile|Coagulation Index Measurement,,,
Cmax ofCoadministeredDrug(90% CI),C2347813|C0439083|C0008107|C3259781|C0439087|C3842582,[qnco]|[qnco]|[geoa]|[lbpr]|[qnco]|[fndg],Cmax|>90|Chile|Coagulation Index Measurement|<90|90%,,,
Cmax ofDidanosine(90% CI),C2347813|C0439083|C0008107|C3259781|C0439087|C3842582,[qnco]|[qnco]|[geoa]|[lbpr]|[qnco]|[fndg],Cmax|>90|Chile|Coagulation Index Measurement|<90|90%,,,
Cmax ofDidanosine(95% CI),C2347813|C0008107|C3259781,[qnco]|[geoa]|[lbpr],Cmax|Chile|Coagulation Index Measurement,,,
Cmax ofCoadministered Drug(95% CI),C2347813|C0013227|C1254351|C0008107|C3259781,[qnco]|[phsu]|[phsu]|[geoa]|[lbpr],Cmax|Pharmaceutical Preparations|Pharmacologic Substance|Chile|Coagulation Index Measurement,,,
Cmax ofStavudine(95% CI),C2347813|C0008107|C3259781,[qnco]|[geoa]|[lbpr],Cmax|Chile|Coagulation Index Measurement,,,
Cmax(ng/mL),C2347813|C0439275,[qnco]|[qnco],Cmax|Microgram per Liter,,,
CmaxSS(Peak plasma concentration),C2347813|C0032105|C1550098|C0444505|C0683150,[qnco]|[bdsu]|[bdsu]|[qnco]|[qnco],"Cmax|Plasma|Plasma, NOS (not otherwise specified)|Peak level|plasma concentration",,,
Cmax,C2347813,[qnco],Cmax,,,
Cmin,C2827771,[qnco],Cmin,,,
Co-administered Drug,C3245499|C1521801|C0013227|C1254351,[geoa]|[ftcn]|[phsu]|[phsu],Colombia|Having administered|Pharmaceutical Preparations|Pharmacologic Substance,,,
Co-administered Drug Dose (Schedule),C3245499|C1521801|C0678766|C0086960,[geoa]|[ftcn]|[qnco]|[inpr],Colombia|Having administered|Drug dose|Schedule (document type),,,
Co-administered Drug,C3245499|C1521801|C0013227|C1254351,[geoa]|[ftcn]|[phsu]|[phsu],Colombia|Having administered|Pharmaceutical Preparations|Pharmacologic Substance,,,
Coadministered Drug,C0013227|C1254351,[phsu]|[phsu],Pharmaceutical Preparations|Pharmacologic Substance,,,
Coadministered Drug,C0013227|C1254351,[phsu]|[phsu],Pharmaceutical Preparations|Pharmacologic Substance,,,
Coadministered drug,C0013227|C1254351,[phsu]|[phsu],Pharmaceutical Preparations|Pharmacologic Substance,,,
CoadministeredDrug,,,,,,
Comments,C0282411|C0947611|C1705247,[inpr]|[inpr]|[cnce],Published Comment|Comment|Comment Domain,,,
Concomitant Drug,C0521115|C0013227|C1254351,[tmco]|[phsu]|[phsu],Simultaneous|Pharmaceutical Preparations|Pharmacologic Substance,,,
Concomitant Drug Class or Food,C0521115|C0013227|C0456387|C1705943|C1254351|C0016452|C3540798,"[tmco]|[phsu]|[inpr]|[clas]|[phsu]|[food]|[imft, phsu]",Simultaneous|Pharmaceutical Preparations|Class|Class (taxonomic)|Pharmacologic Substance|Food|Food allergenic extracts,,,
Concomitant Drug Class: Drug Name,C0521115|C0013227|C0456387|C1705943|C1254351|C0027365|C1547383,[tmco]|[phsu]|[inpr]|[clas]|[phsu]|[inpr]|[inpr],Simultaneous|Pharmaceutical Preparations|Class|Class (taxonomic)|Pharmacologic Substance|Name|Person Name,,,
Concomitant Drug Class:Drug Name,C0521115|C0013227|C0456387|C1705943|C1254351|C0027365|C1547383,[tmco]|[phsu]|[inpr]|[clas]|[phsu]|[inpr]|[inpr],Simultaneous|Pharmaceutical Preparations|Class|Class (taxonomic)|Pharmacologic Substance|Name|Person Name,,,
Concomitant Drug Class:Specific Drugs,C0521115|C0013227|C0456387|C1705943|C1254351|C0205369|C3687832|C1552740,[tmco]|[phsu]|[inpr]|[clas]|[phsu]|[qlco]|[topp]|[inpr],Simultaneous|Pharmaceutical Preparations|Class|Class (taxonomic)|Pharmacologic Substance|Specific qualifier value|Drugs|Entity Determiner - specific,,,
Concomitant Drug Name or Drug Class,C0521115|C0013227|C0027365|C1547383|C1254351|C0456387|C1705943,[tmco]|[phsu]|[inpr]|[inpr]|[phsu]|[inpr]|[clas],Simultaneous|Pharmaceutical Preparations|Name|Person Name|Pharmacologic Substance|Class|Class (taxonomic),,,
Concomitant Drug,C0521115|C0013227|C1254351,[tmco]|[phsu]|[phsu],Simultaneous|Pharmaceutical Preparations|Pharmacologic Substance,,,
ConcomitantDrug,,,,,,
Conjugated Estrogens,C0014938,"[horm, orch, phsu]","Estrogens, Conjugated (USP)",,,
Conjugated Estrogens plus PROMETRIUM Capsules,C0014938|C0876759|C0006935,"[horm, orch, phsu]|[orch, phsu]|[bodm]","Estrogens, Conjugated (USP)|Prometrium|capsule (pharmacologic)",,,
Conjugated Estrogens plus Progesterone Capsules,C0014938|C0033308|C0006935|C2757070,"[horm, orch, phsu]|[horm, orch, phsu]|[bodm]|[phsu]","Estrogens, Conjugated (USP)|Progesterone|capsule (pharmacologic)|Progesterone [EPC]",,,
Corticosteroids,C0001617|C3539185|C3540725|C3540726|C3540727,"[horm, orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]","Adrenal Cortex Hormones|Corticosteroid nasal preparations for topical use|Corticosteroid otologicals|Corticosteroid ophthalmologic and otologic preparations|Corticosteroids, topical for treatment of hemorrhoids and anal fissures",,,
Cyclosporine,C0010592|C0010594,"[aapp, phsu]|[imft, phsu]",Cyclosporine|Cyclosporins,,,
DESCRIPTION OF INTERACTION,C0678257|C1704675,[inpr]|[ftcn],Description|Interaction,,,
DISCRIPTION OF INTERACTION,C1704675,[ftcn],Interaction,,,
Didanosine Dosage,C0012133|C0178602,"[nnon, phsu]|[qnco]",Didanosine|Dosage,,,
DidanosineDosage,,,,,,
Diluent,C1875022,[bodm],DILUENT,,,
Dosage Adjustment of Aripiprazole,C0178602|C0376209|C0456081|C0683269|C0299792,"[qnco]|[inbe]|[ftcn]|[inbe]|[orch, phsu]",Dosage|Individual Adjustment|Adjustment Action|Psychological adjustment|aripiprazole,,,
Dose Regimen of Immediate-Release Nevirapine,C2348331|C1708470|C0132326,"[topp]|[bodm]|[orch, phsu]",Dose Regimen|Immediate Release Dosage Form|Nevirapine,,,
Dose Regimen of Nevirapine,C2348331|C0132326,"[topp]|[orch, phsu]",Dose Regimen|Nevirapine,,,
Dose of AED(mg/day),C0178602|C0869039|C1114758|C0887457|C0439422,"[qnco]|[qnco]|[clna]|[orch, phsu]|[qnco]",Dosage|Unit dose|Dose number:Number:Point in time:^Patient:Quantitative|Cystamine Dihydrochloride|milligram/day,,,
Dose of Azithromycin,C0178602|C0869039|C1114758|C0052796,"[qnco]|[qnco]|[clna]|[antb, orch]",Dosage|Unit dose|Dose number:Number:Point in time:^Patient:Quantitative|Azithromycin,,,
Dose of CRIXIVAN (mg),C0178602|C0869039|C1114758|C0701105|C0026410|C0439269|C1960952|C2346927,"[qnco]|[qnco]|[clna]|[orch, phsu]|[geoa]|[qnco]|[qnco]|[elii, phsu]",Dosage|Unit dose|Dose number:Number:Point in time:^Patient:Quantitative|Crixivan|Mongolia|mg/dL|Milligram percent|Magnesium Cation,,,
Dose of Co-administered Drug,C0178602|C0869039|C1114758|C3245499|C1521801|C0013227|C1254351,[qnco]|[qnco]|[clna]|[geoa]|[ftcn]|[phsu]|[phsu],Dosage|Unit dose|Dose number:Number:Point in time:^Patient:Quantitative|Colombia|Having administered|Pharmaceutical Preparations|Pharmacologic Substance,,,
Dose of Coadministered Drug,C0178602|C0869039|C1114758|C0013227|C1254351,[qnco]|[qnco]|[clna]|[phsu]|[phsu],Dosage|Unit dose|Dose number:Number:Point in time:^Patient:Quantitative|Pharmaceutical Preparations|Pharmacologic Substance,,,
Dose of Coadministered drug (mg),C0178602|C0869039|C1114758|C0013227|C1254351|C0026410|C0439269|C1960952|C2346927,"[qnco]|[qnco]|[clna]|[phsu]|[phsu]|[geoa]|[qnco]|[qnco]|[elii, phsu]",Dosage|Unit dose|Dose number:Number:Point in time:^Patient:Quantitative|Pharmaceutical Preparations|Pharmacologic Substance|Mongolia|mg/dL|Milligram percent|Magnesium Cation,,,
Dose/Schedule of Co-administered Drug,C0178602|C0086960|C0869039|C1114758|C3245499|C1521801|C0013227|C1254351,[qnco]|[inpr]|[qnco]|[clna]|[geoa]|[ftcn]|[phsu]|[phsu],Dosage|Schedule (document type)|Unit dose|Dose number:Number:Point in time:^Patient:Quantitative|Colombia|Having administered|Pharmaceutical Preparations|Pharmacologic Substance,,,
Dosing Recommendations,C0178602|C0034866|C0869039|C1114758,[qnco]|[idcn]|[qnco]|[clna],Dosage|Recommendation|Unit dose|Dose number:Number:Point in time:^Patient:Quantitative,,,
Dosing Schedule,C0178602|C0086960|C0869039|C1114758,[qnco]|[inpr]|[qnco]|[clna],Dosage|Schedule (document type)|Unit dose|Dose number:Number:Point in time:^Patient:Quantitative,,,
Dosing Schedule,C0178602|C0086960|C0869039|C1114758,[qnco]|[inpr]|[qnco]|[clna],Dosage|Schedule (document type)|Unit dose|Dose number:Number:Point in time:^Patient:Quantitative,,,
DosingSchedule,,,,,,
Drug,C0013227|C1254351,[phsu]|[phsu],Pharmaceutical Preparations|Pharmacologic Substance,,,
Drug Class,C0013227|C0456387|C1705943|C1254351,[phsu]|[inpr]|[clas]|[phsu],Pharmaceutical Preparations|Class|Class (taxonomic)|Pharmacologic Substance,,,
Drug Class: Drug Name,C0013227|C0456387|C1705943|C1254351|C0027365|C1547383,[phsu]|[inpr]|[clas]|[phsu]|[inpr]|[inpr],Pharmaceutical Preparations|Class|Class (taxonomic)|Pharmacologic Substance|Name|Person Name,,,
"Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.2, 4, 5.2, 7.1, 7.2, 7.3, 7.4, 12.3)",C0687133|C0332281|C0205217|C0035647|C0442805|C0026848|C0035410|C0740116|C2827735|C2981700|C3833492|C0439084|C0728893,[moft]|[qlco]|[qnco]|[idcn]|[ftcn]|[dsyn]|[patf]|[qnco]|[qnco]|[clas]|[fndg]|[qnco]|[qnco],"Drug Interactions|Associated with|Increased|Risk|Increase|Myopathy|Rhabdomyolysis|+2|2+ Score|2+ Score, WHO|2+|>5|+5",,,
"Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.6, 5.1, 7, 12.3)",C0687133|C0332281|C0205217|C0035647|C0442805|C0026848|C0035410|C0740116|C2827735|C2981700|C3833492|C0439084|C0728893,[moft]|[qlco]|[qnco]|[idcn]|[ftcn]|[dsyn]|[patf]|[qnco]|[qnco]|[clas]|[fndg]|[qnco]|[qnco],"Drug Interactions|Associated with|Increased|Risk|Increase|Myopathy|Rhabdomyolysis|+2|2+ Score|2+ Score, WHO|2+|>5|+5",,,
Drug Name,C0013227|C0027365|C1547383|C1254351,[phsu]|[inpr]|[inpr]|[phsu],Pharmaceutical Preparations|Name|Person Name|Pharmacologic Substance,,,
Drug Name,C0013227|C0027365|C1547383|C1254351,[phsu]|[inpr]|[inpr]|[phsu],Pharmaceutical Preparations|Name|Person Name|Pharmacologic Substance,,,
Drug Plasma Exposure (Cmax and AUC?),C0743284|C0032105|C1550098|C2347813|C0376690,[fndg]|[bdsu]|[bdsu]|[qnco]|[qnco],"drug exposure|Plasma|Plasma, NOS (not otherwise specified)|Cmax|Area Under Curve",,,
Drug Plasma Exposure(Cmax and AUC?),C0743284|C0032105|C1550098|C2347813|C0376690,[fndg]|[bdsu]|[bdsu]|[qnco]|[qnco],"drug exposure|Plasma|Plasma, NOS (not otherwise specified)|Cmax|Area Under Curve",,,
Drug or Drug Class,C0013227|C1254351|C0456387|C1705943,[phsu]|[phsu]|[inpr]|[clas],Pharmaceutical Preparations|Pharmacologic Substance|Class|Class (taxonomic),,,
Drug(s),C0013227|C1254351|C0565930|C2603362,[phsu]|[phsu]|[qnco]|[clna],Pharmaceutical Preparations|Pharmacologic Substance|per second|S prime,,,
Drug(s) Affecting Pharmacokinetics of CIPRO XR,C0013227|C1254351|C0392760|C0031327|C0031328|C1314939|C1170167,"[phsu]|[phsu]|[ftcn]|[phsf]|[ftcn]|[ftcn]|[orch, phsu]",Pharmaceutical Preparations|Pharmacologic Substance|Affecting|Drug Kinetics|Pharmacokinetic aspects|Involvement with|Cipro XR,,,
"Drug(s) Affecting Pharmacokinetics of Ciprofloxacin Tablets, USP",C0013227|C1254351|C0392760|C0031327|C0031328|C1314939|C0008809|C0039225|C1656373|C1706444|C3542434,"[phsu]|[phsu]|[ftcn]|[phsf]|[ftcn]|[ftcn]|[orch, phsu]|[bodm]|[moft]|[hcro]|[inpr]",Pharmaceutical Preparations|Pharmacologic Substance|Affecting|Drug Kinetics|Pharmacokinetic aspects|Involvement with|Ciprofloxacin|Tablet Dosage Form|UTP-monosaccharide-1-phosphate uridylyltransferase activity|United States Pharmacopeia|Urgency Perception Scale Questionnaire,,,
"Drug(s) with Pharmacokinetics Affected by KETEK(Mechanism of interaction, if known)",C0013227|C1254351|C0031327|C0031328|C0392760|C1314939|C1452484|C0441712|C1706376|C1704675|C0205309,"[phsu]|[phsu]|[phsf]|[ftcn]|[ftcn]|[ftcn]|[antb, orch]|[ftcn]|[mnob]|[ftcn]|[qlco]",Pharmaceutical Preparations|Pharmacologic Substance|Drug Kinetics|Pharmacokinetic aspects|Affecting|Involvement with|Ketek|Mechanism (attribute)|Mechanism Component of Device|Interaction|Known,,,
Drug/Drug Class(Mechanism of Interaction by Voriconazole),C4036061|C0456387|C1705943|C0441712|C1706376|C1704675|C0393080,"[fndg]|[inpr]|[clas]|[ftcn]|[mnob]|[ftcn]|[orch, phsu]",Drug-drug|Class|Class (taxonomic)|Mechanism (attribute)|Mechanism Component of Device|Interaction|voriconazole,,,
Drug/Drug Class(Mechanism of Interaction by the Drug),C4036061|C0456387|C1705943|C0441712|C1706376|C1704675|C0013227|C1254351,[fndg]|[inpr]|[clas]|[ftcn]|[mnob]|[ftcn]|[phsu]|[phsu],Drug-drug|Class|Class (taxonomic)|Mechanism (attribute)|Mechanism Component of Device|Interaction|Pharmaceutical Preparations|Pharmacologic Substance,,,
Drug/Drug Class(Mechanism ofInteraction by Voriconazole),C4036061|C0456387|C1705943|C0441712|C1706376|C0393080,"[fndg]|[inpr]|[clas]|[ftcn]|[mnob]|[orch, phsu]",Drug-drug|Class|Class (taxonomic)|Mechanism (attribute)|Mechanism Component of Device|voriconazole,,,
Drug/Drug Class(Mechanism ofInteraction by the Drug),C4036061|C0456387|C1705943|C0441712|C1706376|C0013227|C1254351,[fndg]|[inpr]|[clas]|[ftcn]|[mnob]|[phsu]|[phsu],Drug-drug|Class|Class (taxonomic)|Mechanism (attribute)|Mechanism Component of Device|Pharmaceutical Preparations|Pharmacologic Substance,,,
Drugs Known to Prolong QT Interval,C0013227|C3687832|C0205309|C0040363|C0041260|C1883351|C0429028|C0488414,"[phsu]|[topp]|[qlco]|[geoa]|[aapp, enzy]|[qlco]|[clna]|[clna]",Pharmaceutical Preparations|Drugs|Known|Togo|Tryptophanase|To|QT interval feature (observable entity)|QT interval:Time:Point in time:Heart:Quantitative:EKG,,,
Drugs That Are Affected By KETEK,C0013227|C3687832|C0392760|C1314939|C1452484,"[phsu]|[topp]|[ftcn]|[ftcn]|[antb, orch]",Pharmaceutical Preparations|Drugs|Affecting|Involvement with|Ketek,,,
Drugs That Interfere with Hemostasis,C0013227|C3687832|C0521102|C0019116|C0740166,[phsu]|[topp]|[ftcn]|[ortf]|[topp],Pharmaceutical Preparations|Drugs|Interferes with|Hemostatic function|Hemostasis procedure,,,
Drugs That May Increase the Risk of Hypoglycemia,C0013227|C3687832|C3812381|C0442805|C0035647|C0020615,[phsu]|[topp]|[tmco]|[ftcn]|[idcn]|[dsyn],Pharmaceutical Preparations|Drugs|Month of May|Increase|Risk|Hypoglycemia,,,
Drugs That are Affected by CIPRO,C0013227|C3687832|C0392760|C1314939|C0701042,"[phsu]|[topp]|[ftcn]|[ftcn]|[orch, phsu]",Pharmaceutical Preparations|Drugs|Affecting|Involvement with|Cipro,,,
Drugs That are Affected by CIPRO IV,C0013227|C3687832|C0392760|C1314939|C0701042|C0022326,"[phsu]|[topp]|[ftcn]|[ftcn]|[orch, phsu]|[geoa]",Pharmaceutical Preparations|Drugs|Affecting|Involvement with|Cipro|Ivory Coast,,,
Drugs That are Affected by Ciprofloxacin,C0013227|C3687832|C0392760|C1314939|C0008809,"[phsu]|[topp]|[ftcn]|[ftcn]|[orch, phsu]",Pharmaceutical Preparations|Drugs|Affecting|Involvement with|Ciprofloxacin,,,
"Drugs That are Affected by Ciprofloxacin Tablets, USP",C0013227|C3687832|C0392760|C1314939|C0008809|C0039225|C1656373|C1706444|C3542434,"[phsu]|[topp]|[ftcn]|[ftcn]|[orch, phsu]|[bodm]|[moft]|[hcro]|[inpr]",Pharmaceutical Preparations|Drugs|Affecting|Involvement with|Ciprofloxacin|Tablet Dosage Form|UTP-monosaccharide-1-phosphate uridylyltransferase activity|United States Pharmacopeia|Urgency Perception Scale Questionnaire,,,
"Drugs known to prolong QT interval (e.g., Class IA and Class III anti-arrhythmic agents).",C0013227|C3687832|C0205309|C0040363|C0041260|C1883351|C0429028|C0488414|C0456387|C1947960|C1705943|C0441887|C0003195|C0301380|C2698969,"[phsu]|[topp]|[qlco]|[geoa]|[aapp, enzy]|[qlco]|[clna]|[clna]|[inpr]|[mamm]|[clas]|[inpr]|[phsu]|[phsu]|[fndg]",Pharmaceutical Preparations|Drugs|Known|Togo|Tryptophanase|To|QT interval feature (observable entity)|QT interval:Time:Point in time:Heart:Quantitative:EKG|Class|Ia <mammal>|Class (taxonomic)|Class 3|Anti-Arrhythmia Agents|Cardiac depressant drug|Canadian Cardiovascular Society Grading Scale Class III,,,
Drugs that alter thyroid hormone secretion,C0013227|C3687832|C0392747|C1519510,[phsu]|[topp]|[ftcn]|[ortf],Pharmaceutical Preparations|Drugs|Changing|Thyroid Hormone Secretion Process,,,
Drugs that may alter T 4 and T 3 metabolism,C0013227|C3687832|C0392747|C3641140|C0041014|C0025519|C0025520,"[phsu]|[topp]|[ftcn]|[spco]|[aapp, horm, phsu]|[orgf]|[ftcn]",Pharmaceutical Preparations|Drugs|Changing|Tetrahedral Molecular Geometry|Triiodothyronine|Metabolism|metabolic aspects,,,
Drugs that may alter T 4 and T 3 serum transport - but FT 4 concentration remains normal; ,C0013227|C3687832|C0392747|C3641140|C0041014|C0229671|C0005528|C1317949|C3495449|C1546774|C1550100|C1881534|C0004268|C0086045|C1446561|C3890579|C0205307|C0439166|C2347086,"[phsu]|[topp]|[ftcn]|[spco]|[aapp, horm, phsu]|[bdsu]|[celf]|[mnob]|[medd]|[inpr]|[bdsu]|[ftcn]|[menp]|[menp]|[qnco]|[idcn]|[qlco]|[qnco]|[qnco]",Pharmaceutical Preparations|Drugs|Changing|Tetrahedral Molecular Geometry|Triiodothyronine|Serum|Biological Transport|transport (device)|Mobility aid|Specimen Source Codes - Serum|Specimen Type - Serum|Make - Instruction Imperative|Attention|Mental concentration|Concentration measurement|Functional Tests Domain|Normal|Percent normal|Mean Percent of Normal,,,
Drugs that may alter T 4 and T 3 serum transport - but FT 4 concentration remains normal; ,C0013227|C3687832|C0392747|C3641140|C0041014|C0229671|C0005528|C1317949|C3495449|C1546774|C1550100|C1881534|C0004268|C0086045|C1446561|C3890579|C0205307|C0439166|C2347086,"[phsu]|[topp]|[ftcn]|[spco]|[aapp, horm, phsu]|[bdsu]|[celf]|[mnob]|[medd]|[inpr]|[bdsu]|[ftcn]|[menp]|[menp]|[qnco]|[idcn]|[qlco]|[qnco]|[qnco]","Pharmaceutical Preparations|Drugs|Changing|Tetrahedral Molecular Geometry|Triiodothyronine|Serum|Biological Transport|transport (device)|Mobility aid|Specimen Source Codes - Serum|Specimen Type - Serum|Make - Instruction Imperative|Attention|Mental concentration|Concentration measurement|Functional Tests Domain|Normal|Percent normal|Mean Percent of Normal""and, therefore, the patient remains euthyroid",C0030705|C2360836|C2360838|C2360840|C0117002,"[phsu]|[topp]|[ftcn]|[spco]|[aapp, horm, phsu]|[bdsu]|[celf]|[mnob]|[medd]|[inpr]|[bdsu]|[ftcn]|[menp]|[menp]|[qnco]|[idcn]|[qlco]|[qnco]|[qnco][podg]|[clna]|[clna]|[clna]|[fndg]",Pharmaceutical Preparations|Drugs|Changing|Tetrahedral Molecular Geometry|Triiodothyronine|Serum|Biological Transport|transport (device)|Mobility aid|Specimen Source Codes - Serum|Specimen Type - Serum|Make - Instruction Imperative|Attention|Mental concentration|Concentration measurement|Functional Tests Domain|Normal|Percent normal|Mean Percent of NormalPatients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)
Drugs that may alter T4 and T3 metabolism,C0013227|C3687832|C0392747|C0025519|C0025520,[phsu]|[topp]|[ftcn]|[orgf]|[ftcn],Pharmaceutical Preparations|Drugs|Changing|Metabolism|metabolic aspects,,,
Drugs that may alter T4 and T3 serum transport- but FT4 concentration remains normal; ,C0013227|C3687832|C0392747|C0229671|C0005528|C1317949|C3495449|C1546774|C1550100|C0004268|C0086045|C1446561|C0205307|C0439166|C2347086,[phsu]|[topp]|[ftcn]|[bdsu]|[celf]|[mnob]|[medd]|[inpr]|[bdsu]|[menp]|[menp]|[qnco]|[qlco]|[qnco]|[qnco],Pharmaceutical Preparations|Drugs|Changing|Serum|Biological Transport|transport (device)|Mobility aid|Specimen Source Codes - Serum|Specimen Type - Serum|Attention|Mental concentration|Concentration measurement|Normal|Percent normal|Mean Percent of Normal,,,
Drugs that may alter T4 and T3 serum transport- but FT4 concentration remains normal; ,C0013227|C3687832|C0392747|C0229671|C0005528|C1317949|C3495449|C1546774|C1550100|C0004268|C0086045|C1446561|C0205307|C0439166|C2347086,[phsu]|[topp]|[ftcn]|[bdsu]|[celf]|[mnob]|[medd]|[inpr]|[bdsu]|[menp]|[menp]|[qnco]|[qlco]|[qnco]|[qnco],"Pharmaceutical Preparations|Drugs|Changing|Serum|Biological Transport|transport (device)|Mobility aid|Specimen Source Codes - Serum|Specimen Type - Serum|Attention|Mental concentration|Concentration measurement|Normal|Percent normal|Mean Percent of Normal""and, therefore, the patient remains euthyroid",C0030705|C2360836|C2360838|C2360840|C0117002,[phsu]|[topp]|[ftcn]|[bdsu]|[celf]|[mnob]|[medd]|[inpr]|[bdsu]|[menp]|[menp]|[qnco]|[qlco]|[qnco]|[qnco][podg]|[clna]|[clna]|[clna]|[fndg],Pharmaceutical Preparations|Drugs|Changing|Serum|Biological Transport|transport (device)|Mobility aid|Specimen Source Codes - Serum|Specimen Type - Serum|Attention|Mental concentration|Concentration measurement|Normal|Percent normal|Mean Percent of NormalPatients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)
Drugs that may cause protein-binding site displacement,C0013227|C3687832|C0015127|C1524003|C0033618|C0205145|C0012725|C0012727|C0456080|C2347509|C1515974|C2825164|C0033684|C0005456|C0682969,"[phsu]|[topp]|[ftcn]|[cnce]|[moft]|[spco]|[menp]|[spco]|[qlco]|[phpr]|[blor]|[spco]|[aapp, bacs]|[rcpt]|[amas]",Pharmaceutical Preparations|Drugs|Etiology aspects|Science of Etiology|Protein Binding|Site|Psychologic Displacement|Spatial Displacement|Qualitative Displacement|Physical Shift|Anatomic Site|Study Site|Proteins|Binding Sites|Ligand Binding Domain,,,
Drugs that may decrease,C0013227|C3687832|C0392756|C0547047,[phsu]|[topp]|[qlco]|[qnco],Pharmaceutical Preparations|Drugs|Reduced|Decrease,,,
Drugs that may decrease T 4 5' - deiodinase activity,C0013227|C3687832|C0392756|C0547047|C3641140|C1151530|C2260422|C2260426|C2260427,[phsu]|[topp]|[qlco]|[qnco]|[spco]|[moft]|[moft]|[moft]|[moft],Pharmaceutical Preparations|Drugs|Reduced|Decrease|Tetrahedral Molecular Geometry|iodide peroxidase activity|iodinase activity|thyroperoxidase activity|TPO activity,,,
"Drugs that may decrease T 4 absorption, which may result in hypothyroidism",C0013227|C3687832|C0392756|C0547047|C3641140|C0000854|C2347023|C2347080|C2698776|C2825050|C1274040|C1546471|C2825142|C0020676,[phsu]|[topp]|[qlco]|[qnco]|[spco]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[ftcn]|[idcn]|[fndg]|[dsyn],Pharmaceutical Preparations|Drugs|Reduced|Decrease|Tetrahedral Molecular Geometry|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Result|What subject filter - Result|Experimental Result|Hypothyroidism,,,
Drugs that may decrease T4 5'-deiodinase activity,C0013227|C3687832|C0392756|C0547047|C0039216|C0205177|C0439167|C0441655|C1561536|C3668946|C0039682,"[phsu]|[topp]|[qlco]|[qnco]|[aapp, enzy]|[ftcn]|[qnco]|[acty]|[idcn]|[fndg]|[aapp, enzy]",Pharmaceutical Preparations|Drugs|Reduced|Decrease|T4-Monodeiodinase|Active|Percent Activity|Activities|*Activity (kind of quantity)|Activity (animal life circumstance)|Tetraiodothyronine 5'-Deiodinase,,,
"Drugs that may decrease T4 absorption, which may result in hypothyroidism",C0013227|C3687832|C0392756|C0547047|C0000854|C2347023|C2347080|C2698776|C2825050|C1274040|C1546471|C2825142|C0020676,[phsu]|[topp]|[qlco]|[qnco]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[ftcn]|[idcn]|[fndg]|[dsyn],Pharmaceutical Preparations|Drugs|Reduced|Decrease|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Result|What subject filter - Result|Experimental Result|Hypothyroidism,,,
Drugs that may decrease serum TBG concentration,C0013227|C3687832|C0392756|C0547047|C0683149|C3814864|C1420598|C0004268|C0086045|C1446561,[phsu]|[topp]|[qlco]|[qnco]|[qnco]|[gngm]|[gngm]|[menp]|[menp]|[qnco],Pharmaceutical Preparations|Drugs|Reduced|Decrease|serum concentration|SERPINA7 wt Allele|SERPINA7 gene|Attention|Mental concentration|Concentration measurement,,,
"Drugs that may decrease thyroid hormone secretion, which may result in hypothyroidism",C0013227|C3687832|C0392756|C0547047|C1519510|C1274040|C1546471|C2825142|C0020676,[phsu]|[topp]|[qlco]|[qnco]|[ortf]|[ftcn]|[idcn]|[fndg]|[dsyn],Pharmaceutical Preparations|Drugs|Reduced|Decrease|Thyroid Hormone Secretion Process|Result|What subject filter - Result|Experimental Result|Hypothyroidism,,,
"Drugs that may decrease thyroid hormone secretion, which mayresult in hypothyroidism",C0013227|C3687832|C0392756|C0547047|C1519510|C0020676,[phsu]|[topp]|[qlco]|[qnco]|[ortf]|[dsyn],Pharmaceutical Preparations|Drugs|Reduced|Decrease|Thyroid Hormone Secretion Process|Hypothyroidism,,,
Drugs that may increase,C0013227|C3687832|C0442805,[phsu]|[topp]|[ftcn],Pharmaceutical Preparations|Drugs|Increase,,,
"Drugs that may increase hepatic metabolism, which may result in hypothyroidism",C0013227|C3687832|C0442805|C1373178|C1274040|C1546471|C2825142|C0020676,[phsu]|[topp]|[ftcn]|[ortf]|[ftcn]|[idcn]|[fndg]|[dsyn],Pharmaceutical Preparations|Drugs|Increase|Hepatic Metabolism [PK]|Result|What subject filter - Result|Experimental Result|Hypothyroidism,,,
"Drugs that may increase hepatic metabolism, whichmay resultin hypothyroidism",C0013227|C3687832|C0442805|C1373178|C0020676,[phsu]|[topp]|[ftcn]|[ortf]|[dsyn],Pharmaceutical Preparations|Drugs|Increase|Hepatic Metabolism [PK]|Hypothyroidism,,,
Drugs that may increase serum TBG concentration,C0013227|C3687832|C0442805|C0683149|C3814864|C1420598|C0004268|C0086045|C1446561,[phsu]|[topp]|[ftcn]|[qnco]|[gngm]|[gngm]|[menp]|[menp]|[qnco],Pharmaceutical Preparations|Drugs|Increase|serum concentration|SERPINA7 wt Allele|SERPINA7 gene|Attention|Mental concentration|Concentration measurement,,,
"Drugs that may increase thyroid hormone secretion, which may result in hyperthyroidism",C0013227|C3687832|C0442805|C1519510|C1274040|C1546471|C2825142|C0020550,[phsu]|[topp]|[ftcn]|[ortf]|[ftcn]|[idcn]|[fndg]|[dsyn],Pharmaceutical Preparations|Drugs|Increase|Thyroid Hormone Secretion Process|Result|What subject filter - Result|Experimental Result|Hyperthyroidism,,,
"Drugs that may increase thyroid hormone secretion, whichmay result in hyperthyroidism",C0013227|C3687832|C0442805|C1519510|C1274040|C1546471|C2825142|C0020550,[phsu]|[topp]|[ftcn]|[ortf]|[ftcn]|[idcn]|[fndg]|[dsyn],Pharmaceutical Preparations|Drugs|Increase|Thyroid Hormone Secretion Process|Result|What subject filter - Result|Experimental Result|Hyperthyroidism,,,
Drugs that may reduce TSH secretion - the reduction is not sustained; ,C0013227|C3687832|C2611225|C0301630|C0392756|C0441610|C1518422|C0443318,[phsu]|[topp]|[celf]|[npop]|[qlco]|[topp]|[ftcn]|[ftcn],Pharmaceutical Preparations|Drugs|thyroid-stimulating hormone secretion|Reduction (chemical)|Reduced|Reduction - action|Negation|Sustained,,,
Drugs that may reduce TSH secretion - the reduction is not sustained; ,C0013227|C3687832|C2611225|C0301630|C0392756|C0441610|C1518422|C0443318,[phsu]|[topp]|[celf]|[npop]|[qlco]|[topp]|[ftcn]|[ftcn],"Pharmaceutical Preparations|Drugs|thyroid-stimulating hormone secretion|Reduction (chemical)|Reduced|Reduction - action|Negation|Sustained""therefore, hypothyroidism does not occur",C0020676|C1518422|C1709305|C2745955,[phsu]|[topp]|[celf]|[npop]|[qlco]|[topp]|[ftcn]|[ftcn][dsyn]|[ftcn]|[acty]|[tmco],Pharmaceutical Preparations|Drugs|thyroid-stimulating hormone secretion|Reduction (chemical)|Reduced|Reduction - action|Negation|SustainedHypothyroidism|Negation|Occur (action)|Occurrence
Drugs that may reduce TSH secretion the reduction is not sustained; ,C0013227|C3687832|C2611225|C0301630|C0392756|C0441610|C1518422|C0443318,[phsu]|[topp]|[celf]|[npop]|[qlco]|[topp]|[ftcn]|[ftcn],Pharmaceutical Preparations|Drugs|thyroid-stimulating hormone secretion|Reduction (chemical)|Reduced|Reduction - action|Negation|Sustained,,,
Drugs that may reduce TSH secretion the reduction is not sustained; ,C0013227|C3687832|C2611225|C0301630|C0392756|C0441610|C1518422|C0443318,[phsu]|[topp]|[celf]|[npop]|[qlco]|[topp]|[ftcn]|[ftcn],"Pharmaceutical Preparations|Drugs|thyroid-stimulating hormone secretion|Reduction (chemical)|Reduced|Reduction - action|Negation|Sustained""therefore, hypothyroidism does not occur",C0020676|C1518422|C1709305|C2745955,[phsu]|[topp]|[celf]|[npop]|[qlco]|[topp]|[ftcn]|[ftcn][dsyn]|[ftcn]|[acty]|[tmco],Pharmaceutical Preparations|Drugs|thyroid-stimulating hormone secretion|Reduction (chemical)|Reduced|Reduction - action|Negation|SustainedHypothyroidism|Negation|Occur (action)|Occurrence
Drugs that may reduce TSH secretionthe reduction is not sustained; ,C0013227|C3687832|C0241513|C1518422|C0443318,[phsu]|[topp]|[fndg]|[ftcn]|[ftcn],Pharmaceutical Preparations|Drugs|Decreased TSH|Negation|Sustained,,,
Drugs that may reduce TSH secretionthe reduction is not sustained; ,C0013227|C3687832|C0241513|C1518422|C0443318,[phsu]|[topp]|[fndg]|[ftcn]|[ftcn],"Pharmaceutical Preparations|Drugs|Decreased TSH|Negation|Sustained""therefore, hypothyroidism does not occur",C0020676|C1518422|C1709305|C2745955,[phsu]|[topp]|[fndg]|[ftcn]|[ftcn][dsyn]|[ftcn]|[acty]|[tmco],Pharmaceutical Preparations|Drugs|Decreased TSH|Negation|SustainedHypothyroidism|Negation|Occur (action)|Occurrence
Drugs with a known interaction with colesevelam: Decrease in exposure of coadministered drug,C0013227|C3687832|C0205309|C1704675|C0541155|C0392756|C0547047|C0274281|C0332157|C1254351,"[phsu]|[topp]|[qlco]|[ftcn]|[orch, phsu]|[qlco]|[qnco]|[inpo]|[clna]|[phsu]",Pharmaceutical Preparations|Drugs|Known|Interaction|colesevelam|Reduced|Decrease|Injury due to exposure to external cause|Exposure to|Pharmacologic Substance,,,
Drugs with a known interaction with colesevelam:Decrease in exposure of coadministered drug,C0013227|C3687832|C0205309|C1704675|C0541155|C0392756|C0547047|C0274281|C0332157|C1254351,"[phsu]|[topp]|[qlco]|[ftcn]|[orch, phsu]|[qlco]|[qnco]|[inpo]|[clna]|[phsu]",Pharmaceutical Preparations|Drugs|Known|Interaction|colesevelam|Reduced|Decrease|Injury due to exposure to external cause|Exposure to|Pharmacologic Substance,,,
Drugs:,C0013227|C3687832,[phsu]|[topp],Pharmaceutical Preparations|Drugs,,,
EFFECT,C1280500|C2348382,[qlco]|[qlco],"Effect|Effect, Appearance",,,
Effect,C1280500|C2348382,[qlco]|[qlco],"Effect|Effect, Appearance",,,
Effect on Active Moiety (Risperidone + 9-Hydroxy-Risperidone (RatioChange relative to reference),C1280500|C2348382|C1552018|C0073393|C0700307|C0080103|C0205345|C1547039|C0040363|C0041260|C1883351|C1514811|C1706462,"[qlco]|[qlco]|[chvf]|[orch, phsu]|[inch]|[famg]|[qlco]|[qnco]|[geoa]|[aapp, enzy]|[qlco]|[inpr]|[cnce]","Effect|Effect, Appearance|active moiety|Risperidone|hydroxyl group|Relative (related person)|Relative|*Relative|Togo|Tryptophanase|To|Bibliographic Reference|Reference Object",,,
Effect on Active Moiety(Risperidone + 9- Hydroxy-Risperidone (Ratio*),C1280500|C2348382|C1552018|C0073393|C0700307|C0456603|C1547037,"[qlco]|[qlco]|[chvf]|[orch, phsu]|[inch]|[qnco]|[inpr]","Effect|Effect, Appearance|active moiety|Risperidone|hydroxyl group|Ratio|data type - ratio",,,
Effect on Concentration,C1280500|C2348382|C0004268|C0086045|C1446561,[qlco]|[qlco]|[menp]|[menp]|[qnco],"Effect|Effect, Appearance|Attention|Mental concentration|Concentration measurement",,,
Effect on Concentration of Atazanavir or Concomitant Drug,C1280500|C2348382|C0004268|C0086045|C1446561|C1145759|C0521115|C0013227|C1254351,"[qlco]|[qlco]|[menp]|[menp]|[qnco]|[orch, phsu]|[tmco]|[phsu]|[phsu]","Effect|Effect, Appearance|Attention|Mental concentration|Concentration measurement|Atazanavir|Simultaneous|Pharmaceutical Preparations|Pharmacologic Substance",,,
Effect on Concentration of Etravirine or Concomitant Drug,C1280500|C2348382|C0004268|C0086045|C1446561|C1456409|C0521115|C0013227|C1254351,"[qlco]|[qlco]|[menp]|[menp]|[qnco]|[orch, phsu]|[tmco]|[phsu]|[phsu]","Effect|Effect, Appearance|Attention|Mental concentration|Concentration measurement|etravirine|Simultaneous|Pharmaceutical Preparations|Pharmacologic Substance",,,
Effect on Concentration of Lamotrigine or Concomitant Drug,C1280500|C2348382|C0004268|C0086045|C1446561|C0064636|C0524166|C0521115|C0013227|C1254351,"[qlco]|[qlco]|[menp]|[menp]|[qnco]|[orch, phsu]|[lbpr]|[tmco]|[phsu]|[phsu]","Effect|Effect, Appearance|Attention|Mental concentration|Concentration measurement|lamotrigine|Lamotrigine measurement|Simultaneous|Pharmaceutical Preparations|Pharmacologic Substance",,,
Effect on Concentration of Nevirapine or Concomitant Drug,C1280500|C2348382|C0004268|C0086045|C1446561|C0132326|C0521115|C0013227|C1254351,"[qlco]|[qlco]|[menp]|[menp]|[qnco]|[orch, phsu]|[tmco]|[phsu]|[phsu]","Effect|Effect, Appearance|Attention|Mental concentration|Concentration measurement|Nevirapine|Simultaneous|Pharmaceutical Preparations|Pharmacologic Substance",,,
Effect on Concentration of Rilpivirine or Concomitant Drug,C1280500|C2348382|C0004268|C0086045|C1446561|C1566826|C0521115|C0013227|C1254351,"[qlco]|[qlco]|[menp]|[menp]|[qnco]|[nnon, phsu]|[tmco]|[phsu]|[phsu]","Effect|Effect, Appearance|Attention|Mental concentration|Concentration measurement|Rilpivirine|Simultaneous|Pharmaceutical Preparations|Pharmacologic Substance",,,
Effect on Concentration of Ritonavir or Concomitant Drug,C1280500|C2348382|C0004268|C0086045|C1446561|C0292818|C0521115|C0013227|C1254351,"[qlco]|[qlco]|[menp]|[menp]|[qnco]|[orch, phsu]|[tmco]|[phsu]|[phsu]","Effect|Effect, Appearance|Attention|Mental concentration|Concentration measurement|Ritonavir|Simultaneous|Pharmaceutical Preparations|Pharmacologic Substance",,,
Effect on Concentration of Nevirapine or Concomitant Drug,C1280500|C2348382|C0004268|C0086045|C1446561|C0132326|C0521115|C0013227|C1254351,"[qlco]|[qlco]|[menp]|[menp]|[qnco]|[orch, phsu]|[tmco]|[phsu]|[phsu]","Effect|Effect, Appearance|Attention|Mental concentration|Concentration measurement|Nevirapine|Simultaneous|Pharmaceutical Preparations|Pharmacologic Substance",,,
Effect on concentration of Nevirapine or Concomitant drug,C1280500|C2348382|C0004268|C0086045|C1446561|C0132326|C0521115|C0013227|C1254351,"[qlco]|[qlco]|[menp]|[menp]|[qnco]|[orch, phsu]|[tmco]|[phsu]|[phsu]","Effect|Effect, Appearance|Attention|Mental concentration|Concentration measurement|Nevirapine|Simultaneous|Pharmaceutical Preparations|Pharmacologic Substance",,,
Effect onConcentration of Saquinavir or Concomitant Drug,C1280500|C2348382|C0286738|C0521115|C0013227|C1254351,"[qlco]|[qlco]|[orch, phsu]|[tmco]|[phsu]|[phsu]","Effect|Effect, Appearance|Saquinavir|Simultaneous|Pharmaceutical Preparations|Pharmacologic Substance",,,
Effect onConcentration ofLamotrigine orConcomitant Drug,C1319171,[fndg],Medication response,,,
Effect**,C1280500|C2348382,[qlco]|[qlco],"Effect|Effect, Appearance",,,
EffectonActive Moiety(Risperidone+9- Hydroxy-Risperidone(Ratio*),C0073393|C0700307|C0456603|C1547037,"[orch, phsu]|[inch]|[qnco]|[inpr]",Risperidone|hydroxyl group|Ratio|data type - ratio,,,
EffectonActiveMoiety(Risperidone+9-Hydroxy-Risperidone(Ratio*),C0073393|C0700307|C0456603|C1547037,"[orch, phsu]|[inch]|[qnco]|[inpr]",Risperidone|hydroxyl group|Ratio|data type - ratio,,,
EffectonActiveMoiety(Risperidone+9-Hydroxy-Risperidone(Ratio*),C0073393|C0700307|C0456603|C1547037,"[orch, phsu]|[inch]|[qnco]|[inpr]",Risperidone|hydroxyl group|Ratio|data type - ratio,,,
EffectonConcentrationofLamotrigineor ConcomitantDrug,,,,,,
Enzyme,C0014442,"[enzy, orch]",Enzymes,,,
Enzyme (CYP2D6) Inhibitors,C0014442|C0057223|C1332830|C3887685|C0243077,"[enzy, orch]|[aapp, enzy]|[gngm]|[aapp, enzy]|[chvf]","Enzymes|Cytochrome P-450 CYP2D6|CYP2D6 gene|Cytochrome P450 2D6, human|inhibitors",,,
Enzyme(CYP2D6) Inhibitors,C0014442|C0057223|C1332830|C3887685|C0243077,"[enzy, orch]|[aapp, enzy]|[gngm]|[aapp, enzy]|[chvf]","Enzymes|Cytochrome P-450 CYP2D6|CYP2D6 gene|Cytochrome P450 2D6, human|inhibitors",,,
Enzyme(CYP2D6)Inhibitors,C0014442|C0057223|C1332830|C3887685|C0243077,"[enzy, orch]|[aapp, enzy]|[gngm]|[aapp, enzy]|[chvf]","Enzymes|Cytochrome P-450 CYP2D6|CYP2D6 gene|Cytochrome P450 2D6, human|inhibitors",,,
Enzyme(CYP2D6)Inhibitors,C0014442|C0057223|C1332830|C3887685|C0243077,"[enzy, orch]|[aapp, enzy]|[gngm]|[aapp, enzy]|[chvf]","Enzymes|Cytochrome P-450 CYP2D6|CYP2D6 gene|Cytochrome P450 2D6, human|inhibitors",,,
Enzyme(CYP3A) Inhibitors,C0014442|C3814396|C0243077,"[enzy, orch]|[gngm]|[chvf]",Enzymes|CYP3A Gene Locus|inhibitors,,,
Enzyme(CYP3A)Inhibitors,C0014442|C3814396|C0243077,"[enzy, orch]|[gngm]|[chvf]",Enzymes|CYP3A Gene Locus|inhibitors,,,
Enzyme(CYP3A/PgPinducers)Inducers,C0014442|C3814396|C3898767,"[enzy, orch]|[gngm]|[sbst]",Enzymes|CYP3A Gene Locus|Inducer,,,
Exposure,C0274281|C0332157,[inpo]|[clna],Injury due to exposure to external cause|Exposure to,,,
Factors,C1521761|C2827422,[ftcn]|[cnce],Factor|Mathematical Factor,,,
Factors,C1521761|C2827422,[ftcn]|[cnce],Factor|Mathematical Factor,,,
Females(n=14),C0015780|C0086287|C0369718|C0441922,"[orga]|[popg]|[aapp, imft]|[inpr]",Female|Females|N not otherwise specified Antibody|N+ (tumor staging),,,
Glucocorticoids,C0017710|C3540777|C3540778,"[horm, orch]|[horm, orch, phsu]|[orch, phsu]","Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease",,,
HIV Antiviral Agents,C0019682|C0003451|C0019693|C0019699,[virs]|[phsu]|[dsyn]|[lbtr],HIV|Antiviral Agents|HIV Infections|HIV Seropositivity,,,
HIV Antiviral Agents: Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs),C0019682|C0003451|C0019693|C0019699|C1373120|C3541376,"[virs]|[phsu]|[dsyn]|[lbtr]|[moft]|[orch, phsu]",HIV|Antiviral Agents|HIV Infections|HIV Seropositivity|Non-Nucleoside Reverse Transcriptase Inhibitors [MoA]|Non-nucleoside reverse transcriptase inhibitors,,,
HIV Antiviral Agents: Protease Inhibitors (PIs),C0019682|C0003451|C0019693|C0019699|C0033607|C3540755|C1413284,"[virs]|[phsu]|[dsyn]|[lbtr]|[bacs, phsu]|[phsu]|[gngm]","HIV|Antiviral Agents|HIV Infections|HIV Seropositivity|Protease Inhibitors|Protease inhibitors, direct acting antivirals|CDIPT gene",,,
HIV-1-Antiviral Agents: Nucleoside Reverse Transcriptase Inhibitors (NRTIs),C0019704|C0003451|C1373111,[virs]|[phsu]|[moft],HIV-1|Antiviral Agents|Nucleoside Reverse Transcriptase Inhibitors [MoA],,,
Hepatitis C Antiviral Agents,C0019196|C0003451|C0220847,[dsyn]|[phsu]|[virs],Hepatitis C|Antiviral Agents|Hepatitis C virus,,,
Hepatitis C Antiviral Agents,C0019196|C0003451|C0220847,[dsyn]|[phsu]|[virs],Hepatitis C|Antiviral Agents|Hepatitis C virus,,,
Inducers,C3898767,[sbst],Inducer,,,
"Influence of AED on MHD Concentration(Mean Change, 90% Confidence Interval)",C0021399|C0887457|C0004268|C0086045|C1446561|C0444504|C0392747|C0443172|C1705241|C2347634|C2348143|C0439083|C0009667|C0439087|C3842582,"[idcn]|[orch, phsu]|[menp]|[menp]|[qnco]|[qnco]|[ftcn]|[qnco]|[qnco]|[qnco]|[qnco]|[qnco]|[qnco]|[qnco]|[fndg]",Influentials|Cystamine Dihydrochloride|Attention|Mental concentration|Concentration measurement|Statistical mean|Changing|Changed status|Delta (difference)|Population Mean|Sample Mean|>90|Confidence Intervals|<90|90%,,,
"Influence of Oxcarbazepine on AED Concentration(Mean Change, 90% Confidence Interval)",C0021399|C0069751|C0887457|C0004268|C0086045|C1446561|C0444504|C0392747|C0443172|C1705241|C2347634|C2348143|C0439083|C0009667|C0439087|C3842582,"[idcn]|[orch, phsu]|[orch, phsu]|[menp]|[menp]|[qnco]|[qnco]|[ftcn]|[qnco]|[qnco]|[qnco]|[qnco]|[qnco]|[qnco]|[qnco]|[fndg]",Influentials|oxcarbazepine|Cystamine Dihydrochloride|Attention|Mental concentration|Concentration measurement|Statistical mean|Changing|Changed status|Delta (difference)|Population Mean|Sample Mean|>90|Confidence Intervals|<90|90%,,,
Inhibitors,C0243077,[chvf],inhibitors,,,
Interacting Agents,C0450442|C1254351|C1521826,[chvf]|[phsu]|[inpr],Agent|Pharmacologic Substance|Protocol Agent,,,
Interacting Drug,C0013227|C1254351,[phsu]|[phsu],Pharmaceutical Preparations|Pharmacologic Substance,,,
Interacting DrugInteracting Drug,C0013227|C1254351,[phsu]|[phsu],Pharmaceutical Preparations|Pharmacologic Substance,,,
Interacting Agents,C0450442|C1254351|C1521826,[chvf]|[phsu]|[inpr],Agent|Pharmacologic Substance|Protocol Agent,,,
Interacting Drug,C0013227|C1254351,[phsu]|[phsu],Pharmaceutical Preparations|Pharmacologic Substance,,,
Interacting Drug,C0013227|C1254351,[phsu]|[phsu],Pharmaceutical Preparations|Pharmacologic Substance,,,
InteractingAgents,,,,,,
InteractingDrug,,,,,,
Interaction,C1704675,[ftcn],Interaction,,,
Interaction Drug,C0687133,[moft],Drug Interactions,,,
InteractionInteraction,,,,,,
Interaction,C1704675,[ftcn],Interaction,,,
Known CYP2D6 Poor Metabolizers,C0205309|C0057223|C3845231|C1332830|C3887685,"[qlco]|[aapp, enzy]|[fndg]|[gngm]|[aapp, enzy]","Known|Cytochrome P-450 CYP2D6|Poor metabolizer|CYP2D6 gene|Cytochrome P450 2D6, human",,,
Known CYP2D6 Poor Metabolizers and strong CYP3A4 inhibitors,C0205309|C0057223|C3845231|C1332830|C3887685|C0442821|C3850053,"[qlco]|[aapp, enzy]|[fndg]|[gngm]|[aapp, enzy]|[qlco]|[phsu]","Known|Cytochrome P-450 CYP2D6|Poor metabolizer|CYP2D6 gene|Cytochrome P450 2D6, human|Strong|Cytochrome P-450 CYP3A4 Inhibitors",,,
Males(n=106),C0086582|C0369718|C0441922,"[orga]|[aapp, imft]|[inpr]",Males|N not otherwise specified Antibody|N+ (tumor staging),,,
Mean (SD) Noncompartmental Pharmacokinetic Parameters After Multiple Doses of 5 mg/day in Older Men,C0444504|C2347634|C2348143|C1705911|C0439064|C0178602|C0439084|C0439422|C0728893|C0580836|C0025266,[qnco]|[qnco]|[qnco]|[idcn]|[qnco]|[qnco]|[qnco]|[qnco]|[qnco]|[tmco]|[popg],Statistical mean|Population Mean|Sample Mean|Pharmacokinetic Parameters Domain|Numerous|Dosage|>5|milligram/day|+5|Old|Male population group,,,
Mean (SD) Pharmacokinetic Parameters in Healthy Young Subjects (n=15),C0444504|C2347634|C2348143|C1705911|C1708335|C0332239|C0369718|C0441922,"[qnco]|[qnco]|[qnco]|[idcn]|[popg]|[tmco]|[aapp, imft]|[inpr]",Statistical mean|Population Mean|Sample Mean|Pharmacokinetic Parameters Domain|Healthy Volunteers|Young|N not otherwise specified Antibody|N+ (tumor staging),,,
Mean ( SD),C0444504|C2347634|C2348143|C2699239,[qnco]|[qnco]|[qnco]|[mamm],"Statistical mean|Population Mean|Sample Mean|SD, Rat Strain",,,
Mean AUC,C0444504|C0376690|C2347634|C2348143,[qnco]|[qnco]|[qnco]|[qnco],Statistical mean|Area Under Curve|Population Mean|Sample Mean,,,
Mean Cmax,C0444504|C2347813|C2347634|C2348143,[qnco]|[qnco]|[qnco]|[qnco],Statistical mean|Cmax|Population Mean|Sample Mean,,,
Methotrexate,C0025677,"[orch, phsu]",Methotrexate,,,
Miscellaneous,C0205395|C1706184,[qlco]|[qnco],Miscellaneous|Miscellaneous Potency Unit,,,
NSAIDs,C0003211,[phsu],"Anti-Inflammatory Agents, Non-Steroidal",,,
Name of the Concomitant Drug,C0027365|C1547383|C0521115|C0013227|C1254351,[inpr]|[inpr]|[tmco]|[phsu]|[phsu],Name|Person Name|Simultaneous|Pharmaceutical Preparations|Pharmacologic Substance,,,
Noted or anticipated Outcome,C1316572|C1317574|C3840775|C1274040,[clna]|[inpr]|[fndg]|[ftcn],Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Anticipated|Result,,,
OATP1B1 Inhibitors,C3819042,[moft],Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA],,,
OATP1B1 and BCRP Substrate,C1420131|C3812257|C1332002|C1710236|C3891814|C1704927,[gngm]|[gngm]|[gngm]|[mnob]|[sbst]|[gngm],SLCO1B1 gene|SLCO1B1 wt Allele|ABCG2 gene|Substrate Device Component|Substrate|ABCG2 wt Allele,,,
Oral antidiabetic drugs,C0029167|C0935929|C0175795|C0304289|C0442027,[bmod]|[phsu]|[topp]|[phsu]|[spco],Oral Medicine|Antidiabetics|oral medication|Oral drug preparation|Oral,,,
Oral drugs for which sevelamer did not alter the pharmacokinetics when administered concomitantly,C0029167|C0175795|C0304289|C0718050|C1518422|C0392747|C0031327|C0031328|C1521801,"[bmod]|[topp]|[phsu]|[orch, phsu]|[ftcn]|[ftcn]|[phsf]|[ftcn]|[ftcn]",Oral Medicine|oral medication|Oral drug preparation|sevelamer|Negation|Changing|Drug Kinetics|Pharmacokinetic aspects|Having administered,,,
Oral drugs that are to be separated from Velphoro and meals,C0029167|C0175795|C0304289|C0040363|C0041260|C1883351|C0086972|C0443299|C0687118|C3696395|C1998602,"[bmod]|[topp]|[phsu]|[geoa]|[aapp, enzy]|[qlco]|[fndg]|[qlco]|[ftcn]|[phsu]|[dora]",Oral Medicine|oral medication|Oral drug preparation|Togo|Tryptophanase|To|Separated from cohabitee|Separate|Detached|Velphoro|Meal (occasion for eating),,,
Oral drugs that have demonstrated interaction with sevelamer and are to be dosed separately from Renagel,C0029167|C0175795|C0304289|C1704675|C0718050|C0040363|C0041260|C1883351|C0178602|C0869039|C1114758|C0526563,"[bmod]|[topp]|[phsu]|[ftcn]|[orch, phsu]|[geoa]|[aapp, enzy]|[qlco]|[qnco]|[qnco]|[clna]|[orch, phsu]",Oral Medicine|oral medication|Oral drug preparation|Interaction|sevelamer|Togo|Tryptophanase|To|Dosage|Unit dose|Dose number:Number:Point in time:^Patient:Quantitative|RenaGel,,,
Oral drugs that have demonstrated interaction with sevelamer and are to be dosed separately from Renvela,C0029167|C0175795|C0304289|C1704675|C0718050|C0040363|C0041260|C1883351|C0178602|C0869039|C1114758|C1968327,"[bmod]|[topp]|[phsu]|[ftcn]|[orch, phsu]|[geoa]|[aapp, enzy]|[qlco]|[qnco]|[qnco]|[clna]|[orch, phsu]",Oral Medicine|oral medication|Oral drug preparation|Interaction|sevelamer|Togo|Tryptophanase|To|Dosage|Unit dose|Dose number:Number:Point in time:^Patient:Quantitative|Renvela,,,
Oral drugs that have to be separated from Auryxia and meals,C0029167|C0175795|C0304289|C0040363|C0041260|C1883351|C0086972|C0443299|C0687118|C3864953|C1998602,"[bmod]|[topp]|[phsu]|[geoa]|[aapp, enzy]|[qlco]|[fndg]|[qlco]|[ftcn]|[phsu]|[dora]",Oral Medicine|oral medication|Oral drug preparation|Togo|Tryptophanase|To|Separated from cohabitee|Separate|Detached|Auryxia|Meal (occasion for eating),,,
Oral drugs that have to be separated from Phoslyra,C0029167|C0175795|C0304289|C0040363|C0041260|C1883351|C0086972|C0443299|C0687118|C3153639,"[bmod]|[topp]|[phsu]|[geoa]|[aapp, enzy]|[qlco]|[fndg]|[qlco]|[ftcn]|[inch, phsu]",Oral Medicine|oral medication|Oral drug preparation|Togo|Tryptophanase|To|Separated from cohabitee|Separate|Detached|Phoslyra,,,
Oral drugs thathave demonstrated interaction with sevelamer and are to be dosed separately from Renvela,C0029167|C1704675|C0175795|C0304289|C0718050|C0040363|C0041260|C1883351|C0178602|C0869039|C1114758|C1968327,"[bmod]|[ftcn]|[topp]|[phsu]|[orch, phsu]|[geoa]|[aapp, enzy]|[qlco]|[qnco]|[qnco]|[clna]|[orch, phsu]",Oral Medicine|Interaction|oral medication|Oral drug preparation|sevelamer|Togo|Tryptophanase|To|Dosage|Unit dose|Dose number:Number:Point in time:^Patient:Quantitative|Renvela,,,
Other Agents,C0450442|C1254351|C1521826,[chvf]|[phsu]|[inpr],Agent|Pharmacologic Substance|Protocol Agent,,,
Other Drugs /  Dietary Supplements,C0013227|C0242295|C3687832,[phsu]|[food]|[topp],Pharmaceutical Preparations|Dietary Supplements|Drugs,,,
Other Drugs/Dietary Supplements,C0013227|C0242295|C3687832,[phsu]|[food]|[topp],Pharmaceutical Preparations|Dietary Supplements|Drugs,,,
Oxcarbazepine Dose(mg/day),C0069751|C0178602|C0869039|C1114758|C0439422,"[orch, phsu]|[qnco]|[qnco]|[clna]|[qnco]",oxcarbazepine|Dosage|Unit dose|Dose number:Number:Point in time:^Patient:Quantitative|milligram/day,,,
Prescribing Recommendations,C0278329|C0034866,[hlca]|[idcn],prescribed|Recommendation,,,
Prescribing Recommendations for LIPTRUZET,C0278329|C0034866|C3643634,"[hlca]|[idcn]|[orch, phsu]",prescribed|Recommendation|Liptruzet,,,
Prescribing Recommendations,C0278329|C0034866,[hlca]|[idcn],prescribed|Recommendation,,,
PrescribingRecommendations,,,,,,
PrescribingRecommendations,,,,,,
Radiographic Agents,C0444708|C0450442|C1254351|C1521826,[npop]|[chvf]|[phsu]|[inpr],Radiographic|Agent|Pharmacologic Substance|Protocol Agent,,,
Ratio (90% Confidence Interval) of Co-administered DrugPharmacokinetic Parameters with/withouttipranavir/ritonavir; ,C0456603|C1547037|C0439083|C0009667|C0439087|C3842582|C3245499|C1521801|C0449381|C0292818,"[qnco]|[inpr]|[qnco]|[qnco]|[qnco]|[fndg]|[geoa]|[ftcn]|[fndg]|[orch, phsu]",Ratio|data type - ratio|>90|Confidence Intervals|<90|90%|Colombia|Having administered|Observation parameter|Ritonavir,,,
Ratio (90% Confidence Interval) of Co-administered DrugPharmacokinetic Parameters with/withouttipranavir/ritonavir; ,C0456603|C1547037|C0439083|C0009667|C0439087|C3842582|C3245499|C1521801|C0449381|C0292818,"[qnco]|[inpr]|[qnco]|[qnco]|[qnco]|[fndg]|[geoa]|[ftcn]|[fndg]|[orch, phsu]","Ratio|data type - ratio|>90|Confidence Intervals|<90|90%|Colombia|Having administered|Observation parameter|Ritonavir""No Effect = 1.00",C1280500|C2348382|C2827734|C2981698|C3816745,"[qnco]|[inpr]|[qnco]|[qnco]|[qnco]|[fndg]|[geoa]|[ftcn]|[fndg]|[orch, phsu][qlco]|[qlco]|[qnco]|[clas]|[fndg]","Ratio|data type - ratio|>90|Confidence Intervals|<90|90%|Colombia|Having administered|Observation parameter|RitonavirEffect|Effect, Appearance|1+ Score|1+ Score, WHO|1+"
Ratio (90% Confidence Interval) of Tipranavir Pharmacokinetic Parameters with/withoutCo-administered Drug; ,C0456603|C1547037|C0439083|C0009667|C0439087|C3842582|C0663733|C1705911|C1521801|C0013227|C1254351,"[qnco]|[inpr]|[qnco]|[qnco]|[qnco]|[fndg]|[orch, phsu]|[idcn]|[ftcn]|[phsu]|[phsu]",Ratio|data type - ratio|>90|Confidence Intervals|<90|90%|tipranavir|Pharmacokinetic Parameters Domain|Having administered|Pharmaceutical Preparations|Pharmacologic Substance,,,
Ratio (90% Confidence Interval) of Tipranavir Pharmacokinetic Parameters with/withoutCo-administered Drug; ,C0456603|C1547037|C0439083|C0009667|C0439087|C3842582|C0663733|C1705911|C1521801|C0013227|C1254351,"[qnco]|[inpr]|[qnco]|[qnco]|[qnco]|[fndg]|[orch, phsu]|[idcn]|[ftcn]|[phsu]|[phsu]","Ratio|data type - ratio|>90|Confidence Intervals|<90|90%|tipranavir|Pharmacokinetic Parameters Domain|Having administered|Pharmaceutical Preparations|Pharmacologic Substance""No Effect = 1.00",C1280500|C2348382|C2827734|C2981698|C3816745,"[qnco]|[inpr]|[qnco]|[qnco]|[qnco]|[fndg]|[orch, phsu]|[idcn]|[ftcn]|[phsu]|[phsu][qlco]|[qlco]|[qnco]|[clas]|[fndg]","Ratio|data type - ratio|>90|Confidence Intervals|<90|90%|tipranavir|Pharmacokinetic Parameters Domain|Having administered|Pharmaceutical Preparations|Pharmacologic SubstanceEffect|Effect, Appearance|1+ Score|1+ Score, WHO|1+"
Ratio (with/without CRIXIVAN) of Coadministered DrugPharmacokinetic Parameters (90% CI); ,C0456603|C1547037|C0701105|C0449381|C0439083|C0008107|C3259781|C0439087|C3842582,"[qnco]|[inpr]|[orch, phsu]|[fndg]|[qnco]|[geoa]|[lbpr]|[qnco]|[fndg]",Ratio|data type - ratio|Crixivan|Observation parameter|>90|Chile|Coagulation Index Measurement|<90|90%,,,
Ratio (with/without CRIXIVAN) of Coadministered DrugPharmacokinetic Parameters (90% CI); ,C0456603|C1547037|C0701105|C0449381|C0439083|C0008107|C3259781|C0439087|C3842582,"[qnco]|[inpr]|[orch, phsu]|[fndg]|[qnco]|[geoa]|[lbpr]|[qnco]|[fndg]","Ratio|data type - ratio|Crixivan|Observation parameter|>90|Chile|Coagulation Index Measurement|<90|90%""No Effect = 1.00",C1280500|C2348382|C2827734|C2981698|C3816745,"[qnco]|[inpr]|[orch, phsu]|[fndg]|[qnco]|[geoa]|[lbpr]|[qnco]|[fndg][qlco]|[qlco]|[qnco]|[clas]|[fndg]","Ratio|data type - ratio|Crixivan|Observation parameter|>90|Chile|Coagulation Index Measurement|<90|90%Effect|Effect, Appearance|1+ Score|1+ Score, WHO|1+"
Ratio (with/without azithromycin) of Coadministered Drug Pharmacokinetic Parameters (90% CI); ,C0456603|C1547037|C0052796|C0013227|C1705911|C1254351|C0439083|C0008107|C3259781|C0439087|C3842582,"[qnco]|[inpr]|[antb, orch]|[phsu]|[idcn]|[phsu]|[qnco]|[geoa]|[lbpr]|[qnco]|[fndg]",Ratio|data type - ratio|Azithromycin|Pharmaceutical Preparations|Pharmacokinetic Parameters Domain|Pharmacologic Substance|>90|Chile|Coagulation Index Measurement|<90|90%,,,
Ratio (with/without azithromycin) of Coadministered Drug Pharmacokinetic Parameters (90% CI); ,C0456603|C1547037|C0052796|C0013227|C1705911|C1254351|C0439083|C0008107|C3259781|C0439087|C3842582,"[qnco]|[inpr]|[antb, orch]|[phsu]|[idcn]|[phsu]|[qnco]|[geoa]|[lbpr]|[qnco]|[fndg]","Ratio|data type - ratio|Azithromycin|Pharmaceutical Preparations|Pharmacokinetic Parameters Domain|Pharmacologic Substance|>90|Chile|Coagulation Index Measurement|<90|90%""No Effect = 1.00",C1280500|C2348382|C2827734|C2981698|C3816745,"[qnco]|[inpr]|[antb, orch]|[phsu]|[idcn]|[phsu]|[qnco]|[geoa]|[lbpr]|[qnco]|[fndg][qlco]|[qlco]|[qnco]|[clas]|[fndg]","Ratio|data type - ratio|Azithromycin|Pharmaceutical Preparations|Pharmacokinetic Parameters Domain|Pharmacologic Substance|>90|Chile|Coagulation Index Measurement|<90|90%Effect|Effect, Appearance|1+ Score|1+ Score, WHO|1+"
Ratio (with/without coadministered drug) of Azithromycin Pharmacokinetic Parameters (90% CI); ,C0456603|C1547037|C0013227|C1254351|C0052796|C1705911|C0439083|C0008107|C3259781|C0439087|C3842582,"[qnco]|[inpr]|[phsu]|[phsu]|[antb, orch]|[idcn]|[qnco]|[geoa]|[lbpr]|[qnco]|[fndg]",Ratio|data type - ratio|Pharmaceutical Preparations|Pharmacologic Substance|Azithromycin|Pharmacokinetic Parameters Domain|>90|Chile|Coagulation Index Measurement|<90|90%,,,
Ratio (with/without coadministered drug) of Azithromycin Pharmacokinetic Parameters (90% CI); ,C0456603|C1547037|C0013227|C1254351|C0052796|C1705911|C0439083|C0008107|C3259781|C0439087|C3842582,"[qnco]|[inpr]|[phsu]|[phsu]|[antb, orch]|[idcn]|[qnco]|[geoa]|[lbpr]|[qnco]|[fndg]","Ratio|data type - ratio|Pharmaceutical Preparations|Pharmacologic Substance|Azithromycin|Pharmacokinetic Parameters Domain|>90|Chile|Coagulation Index Measurement|<90|90%""No Effect = 1.00",C1280500|C2348382|C2827734|C2981698|C3816745,"[qnco]|[inpr]|[phsu]|[phsu]|[antb, orch]|[idcn]|[qnco]|[geoa]|[lbpr]|[qnco]|[fndg][qlco]|[qlco]|[qnco]|[clas]|[fndg]","Ratio|data type - ratio|Pharmaceutical Preparations|Pharmacologic Substance|Azithromycin|Pharmacokinetic Parameters Domain|>90|Chile|Coagulation Index Measurement|<90|90%Effect|Effect, Appearance|1+ Score|1+ Score, WHO|1+"
Ratio (with/without coadministered drug) of IndinavirPharmacokinetic Parameters (90% CI); ,C0456603|C1547037|C0013227|C1254351|C0449381|C0439083|C0008107|C3259781|C0439087|C3842582,[qnco]|[inpr]|[phsu]|[phsu]|[fndg]|[qnco]|[geoa]|[lbpr]|[qnco]|[fndg],Ratio|data type - ratio|Pharmaceutical Preparations|Pharmacologic Substance|Observation parameter|>90|Chile|Coagulation Index Measurement|<90|90%,,,
Ratio (with/without coadministered drug) of IndinavirPharmacokinetic Parameters (90% CI); ,C0456603|C1547037|C0013227|C1254351|C0449381|C0439083|C0008107|C3259781|C0439087|C3842582,[qnco]|[inpr]|[phsu]|[phsu]|[fndg]|[qnco]|[geoa]|[lbpr]|[qnco]|[fndg],"Ratio|data type - ratio|Pharmaceutical Preparations|Pharmacologic Substance|Observation parameter|>90|Chile|Coagulation Index Measurement|<90|90%""No Effect = 1.00",C1280500|C2348382|C2827734|C2981698|C3816745,[qnco]|[inpr]|[phsu]|[phsu]|[fndg]|[qnco]|[geoa]|[lbpr]|[qnco]|[fndg][qlco]|[qlco]|[qnco]|[clas]|[fndg],"Ratio|data type - ratio|Pharmaceutical Preparations|Pharmacologic Substance|Observation parameter|>90|Chile|Coagulation Index Measurement|<90|90%Effect|Effect, Appearance|1+ Score|1+ Score, WHO|1+"
Recommendation,C0034866,[idcn],Recommendation,,,
Recommendation(Exposure),C0034866|C0274281|C0332157,[idcn]|[inpo]|[clna],Recommendation|Injury due to exposure to external cause|Exposure to,,,
Recommendations for Drug Dosage Adjustment/Comments,C0034866|C0870450|C0376209|C0282411|C0947611|C1705247|C0456081|C0683269,[idcn]|[qnco]|[inbe]|[inpr]|[inpr]|[cnce]|[ftcn]|[inbe],Recommendation|drug dosages|Individual Adjustment|Published Comment|Comment|Comment Domain|Adjustment Action|Psychological adjustment,,,
Recommendations for DrugDosage Adjustment/Comments,C0034866|C0376209|C0282411|C0947611|C1705247|C0456081|C0683269,[idcn]|[inbe]|[inpr]|[inpr]|[cnce]|[ftcn]|[inbe],Recommendation|Individual Adjustment|Published Comment|Comment|Comment Domain|Adjustment Action|Psychological adjustment,,,
Recommendations for Voriconazole Dosage Adjustment/Comments,C0034866|C0393080|C0178602|C0376209|C0282411|C0947611|C1705247|C0456081|C0683269,"[idcn]|[orch, phsu]|[qnco]|[inbe]|[inpr]|[inpr]|[cnce]|[ftcn]|[inbe]",Recommendation|voriconazole|Dosage|Individual Adjustment|Published Comment|Comment|Comment Domain|Adjustment Action|Psychological adjustment,,,
Recommendations for VoriconazoleDosage Adjustment/Comments,C0034866|C0376209|C0282411|C0947611|C1705247|C0456081|C0683269,[idcn]|[inbe]|[inpr]|[inpr]|[cnce]|[ftcn]|[inbe],Recommendation|Individual Adjustment|Published Comment|Comment|Comment Domain|Adjustment Action|Psychological adjustment,,,
Recommendations forVoriconazole Dosage Adjustment/Comments,C0034866|C0178602|C0376209|C0282411|C0947611|C1705247|C0456081|C0683269,[idcn]|[qnco]|[inbe]|[inpr]|[inpr]|[cnce]|[ftcn]|[inbe],Recommendation|Dosage|Individual Adjustment|Published Comment|Comment|Comment Domain|Adjustment Action|Psychological adjustment,,,
Risperidone Dose Recommendation,C0073393|C0178602|C0034866|C0869039|C1114758,"[orch, phsu]|[qnco]|[idcn]|[qnco]|[clna]",Risperidone|Dosage|Recommendation|Unit dose|Dose number:Number:Point in time:^Patient:Quantitative,,,
Risperidone Dose Recommendation,C0073393|C0178602|C0034866|C0869039|C1114758,"[orch, phsu]|[qnco]|[idcn]|[qnco]|[clna]",Risperidone|Dosage|Recommendation|Unit dose|Dose number:Number:Point in time:^Patient:Quantitative,,,
RisperidoneDose Recommendation,C0034866,[idcn],Recommendation,,,
RisperidoneDoseRecommendation,,,,,,
Specific Drugs,C0205369|C0013227|C3687832|C1552740,[qlco]|[phsu]|[topp]|[inpr],Specific qualifier value|Pharmaceutical Preparations|Drugs|Entity Determiner - specific,,,
Specific Drugs Reported,C0205369|C0013227|C3687832|C1552740|C0684224|C0700287,[qlco]|[phsu]|[topp]|[inpr]|[inpr]|[hlca],Specific qualifier value|Pharmaceutical Preparations|Drugs|Entity Determiner - specific|Report (document)|Reporting,,,
Stavudine Dosage,C0164662|C0178602,"[nnon, phsu]|[qnco]",Stavudine|Dosage,,,
"Strong CYP3A4 Inducers (e.g., carbamazepine, rifampin)",C0442821|C3850041|C0006949|C0682993|C0035608,"[qlco]|[phsu]|[orch, phsu]|[orch]|[antb, orch]",Strong|Cytochrome P-450 CYP3A4 Inducers|Carbamazepine|carbamazepin|Rifampin,,,
"Strong CYP3A4 Inhibitors (e.g., itraconazole, clarithromycin) or strong CYP2D6 inhibitors (e.g., quinidine, fluoxetine, paroxetine)",C0442821|C3850053|C0064113|C0055856|C2962190|C3850058|C0034414|C0016365|C0070122,"[qlco]|[phsu]|[orch, phsu]|[antb, orch]|[moft]|[phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]",Strong|Cytochrome P-450 CYP3A4 Inhibitors|Itraconazole|Clarithromycin|Cytochrome P450 2D6 Inhibitors [MoA]|Cytochrome P-450 CYP2D6 Inhibitors|Quinidine|Fluoxetine|Paroxetine,,,
"Strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors,boceprevir, telaprevir, nefazodone), gemfibrozil, cyclosporine, danazol",C0442821|C3850053|C0064113|C0022625|C0936148|C0393080|C0014806|C0055856|C0907410|C0162714|C2756991|C1738934|C1876229|C0068485|C0017245|C0010592|C0010594|C0010961,"[qlco]|[phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[antb, orch]|[antb, orch]|[antb, orch]|[phsu]|[moft]|[aapp, phsu]|[aapp, phsu]|[orch, phsu]|[orch, phsu]|[aapp, phsu]|[imft, phsu]|[horm, orch, phsu]",Strong|Cytochrome P-450 CYP3A4 Inhibitors|Itraconazole|Ketoconazole|posaconazole|voriconazole|Erythromycin|Clarithromycin|telithromycin|HIV Protease Inhibitors|HIV Protease Inhibitors [MoA]|boceprevir|telaprevir|nefazodone|Gemfibrozil|Cyclosporine|Cyclosporins|Danazol,,,
"StrongCYP3A4inhibitors(e.g.,itraconazole,ketoconazole,posaconazole,voriconazole,erythromycin,clarithromycin,telithromycin,HIVproteaseinhibitors,boceprevir,telaprevir,nefazodone,cobicistatcontainingproducts),gemfibrozil,cyclosporine,danazol",C0064113|C0022625|C0936148|C0393080|C0014806|C0055856|C0907410|C1738934|C1876229|C0068485|C0017245|C0010592|C0010594|C0010961,"[orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[antb, orch]|[antb, orch]|[antb, orch]|[aapp, phsu]|[aapp, phsu]|[orch, phsu]|[orch, phsu]|[aapp, phsu]|[imft, phsu]|[horm, orch, phsu]",Itraconazole|Ketoconazole|posaconazole|voriconazole|Erythromycin|Clarithromycin|telithromycin|boceprevir|telaprevir|nefazodone|Gemfibrozil|Cyclosporine|Cyclosporins|Danazol,,,
Sympathomimetics,C0039052,[phsu],Sympathomimetics,,,
TOPAMAX Concentration,C0723778|C0004268|C0086045|C1446561,"[orch, phsu]|[menp]|[menp]|[qnco]",Topamax|Attention|Mental concentration|Concentration measurement,,,
Tmax(hr),C2348796,[qnco],Tmax,,,
Topiramate Concentration,C0076829|C0004268|C0086045|C1446561,"[orch, phsu]|[menp]|[menp]|[qnco]",topiramate|Attention|Mental concentration|Concentration measurement,,,
TopiramateConcentration,,,,,,
Topiramate Concentration,C0076829|C0004268|C0086045|C1446561,"[orch, phsu]|[menp]|[menp]|[qnco]",topiramate|Attention|Mental concentration|Concentration measurement,,,
TopiramateConcentration,,,,,,
Type Of Interaction,C0332307|C1547052|C1704675,[qlco]|[qnco]|[ftcn],Type - attribute|*Type - Kind of quantity|Interaction,,,
Type of Interaction,C0332307|C1547052|C1704675,[qlco]|[qnco]|[ftcn],Type - attribute|*Type - Kind of quantity|Interaction,,,
Vardenafil 10 mgPlacebo-subtracted,C0971579|C3842590|C1719767|C2348589,"[orch, phsu]|[fndg]|[inpr]|[phpr]",vardenafil|10%|Subtract - dosing instruction fragment|Subtraction process,,,
Vardenafil 20 mgPlacebo-subtracted,C0971579|C3842589|C1719767|C2348589,"[orch, phsu]|[fndg]|[inpr]|[phpr]",vardenafil|20%|Subtract - dosing instruction fragment|Subtraction process,,,
Vardenafil10 mgPlacebo-Subtracted,C1719767|C2348589,[inpr]|[phpr],Subtract - dosing instruction fragment|Subtraction process,,,
Vardenafil20 mgPlacebo-Subtracted,C1719767|C2348589,[inpr]|[phpr],Subtract - dosing instruction fragment|Subtraction process,,,
Voriconazole Plasma Exposure (Cmax and AUC? after 200 mg q12h),C0393080|C0032105|C0274281|C0332157|C1550098|C2347813|C0376690|C0026410|C0585327|C0439269|C1960952|C2346927,"[orch, phsu]|[bdsu]|[inpo]|[clna]|[bdsu]|[qnco]|[qnco]|[geoa]|[tmco]|[qnco]|[qnco]|[elii, phsu]","voriconazole|Plasma|Injury due to exposure to external cause|Exposure to|Plasma, NOS (not otherwise specified)|Cmax|Area Under Curve|Mongolia|Every twelve hours|mg/dL|Milligram percent|Magnesium Cation",,,
Voriconazole Plasma Exposure(Cmax and AUC? ,C0393080|C0032105|C0274281|C0332157|C1550098|C2347813|C0376690,"[orch, phsu]|[bdsu]|[inpo]|[clna]|[bdsu]|[qnco]|[qnco]","voriconazole|Plasma|Injury due to exposure to external cause|Exposure to|Plasma, NOS (not otherwise specified)|Cmax|Area Under Curve",,,
Voriconazole Plasma Exposure(Cmax and AUC? ,C0393080|C0032105|C0274281|C0332157|C1550098|C2347813|C0376690,"[orch, phsu]|[bdsu]|[inpo]|[clna]|[bdsu]|[qnco]|[qnco]","voriconazole|Plasma|Injury due to exposure to external cause|Exposure to|Plasma, NOS (not otherwise specified)|Cmax|Area Under Curve""after 200 mg q12h)",C0026410|C0585327|C0439269|C1960952|C2346927,"[orch, phsu]|[bdsu]|[inpo]|[clna]|[bdsu]|[qnco]|[qnco][geoa]|[tmco]|[qnco]|[qnco]|[elii, phsu]","voriconazole|Plasma|Injury due to exposure to external cause|Exposure to|Plasma, NOS (not otherwise specified)|Cmax|Area Under CurveMongolia|Every twelve hours|mg/dL|Milligram percent|Magnesium Cation"
Voriconazole Plasma Exposure(Cmax and AUC? ,C0393080|C0032105|C0274281|C0332157|C1550098|C2347813|C0376690,"[orch, phsu]|[bdsu]|[inpo]|[clna]|[bdsu]|[qnco]|[qnco]","voriconazole|Plasma|Injury due to exposure to external cause|Exposure to|Plasma, NOS (not otherwise specified)|Cmax|Area Under Curve",,,
Voriconazole Plasma Exposure(Cmax and AUC? ,C0393080|C0032105|C0274281|C0332157|C1550098|C2347813|C0376690,"[orch, phsu]|[bdsu]|[inpo]|[clna]|[bdsu]|[qnco]|[qnco]","voriconazole|Plasma|Injury due to exposure to external cause|Exposure to|Plasma, NOS (not otherwise specified)|Cmax|Area Under Curve""after200 mg Q12h)",C0026410|C0585327|C0439269|C1960952|C2346927,"[orch, phsu]|[bdsu]|[inpo]|[clna]|[bdsu]|[qnco]|[qnco][geoa]|[tmco]|[qnco]|[qnco]|[elii, phsu]","voriconazole|Plasma|Injury due to exposure to external cause|Exposure to|Plasma, NOS (not otherwise specified)|Cmax|Area Under CurveMongolia|Every twelve hours|mg/dL|Milligram percent|Magnesium Cation"
Voriconazole PlasmaExposure(Cmax and AUC? ,C0393080|C2347813|C0376690,"[orch, phsu]|[qnco]|[qnco]",voriconazole|Cmax|Area Under Curve,,,
Voriconazole PlasmaExposure(Cmax and AUC? ,C0393080|C2347813|C0376690,"[orch, phsu]|[qnco]|[qnco]","voriconazole|Cmax|Area Under Curve""after200 mg q12h)",C0026410|C0585327|C0439269|C1960952|C2346927,"[orch, phsu]|[qnco]|[qnco][geoa]|[tmco]|[qnco]|[qnco]|[elii, phsu]",voriconazole|Cmax|Area Under CurveMongolia|Every twelve hours|mg/dL|Milligram percent|Magnesium Cation
blood dyscrasias - see cancer collagen vascular disease congestive heart failureCONTRAINDICATIONS,C0018939|C0042789|C1947903|C0006826|C0262428|C0742742|C0018787|C1281570|C0009325|C0005847|C0018802|C1558950|C1801960|C0998265|C1306459,[dsyn]|[orgf]|[acty]|[neop]|[dsyn]|[qlco]|[bpoc]|[bpoc]|[aapp]|[bpoc]|[dsyn]|[fndg]|[qlco]|[euka]|[neop],Hematological Disease|Vision|See|Malignant Neoplasms|collagen vascular disease|congestive|Heart|Entire heart|Collagen|Blood Vessel|Congestive heart failure|Adverse Event Associated with Vascular|Vascular|Cancer Genus|Primary malignant neoplasm,,,
blood dyscrasias - seeCONTRAINDICATIONS cancercollagen vascular diseasecongestive heart failure,C0018939|C0018801|C0018802,[dsyn]|[dsyn]|[dsyn],Hematological Disease|Heart failure|Congestive heart failure,,,
blood dyscrasias -see CONTRAINDICATIONS cancercollagen vascular diseasecongestive heart failure,C0018939|C0042789|C1947903|C0079164|C0005847|C0018801|C0018802|C1558950|C1801960,[dsyn]|[orgf]|[acty]|[qlco]|[bpoc]|[dsyn]|[dsyn]|[fndg]|[qlco],Hematological Disease|Vision|See|contraindications aspect|Blood Vessel|Heart failure|Congestive heart failure|Adverse Event Associated with Vascular|Vascular,,,
edema hereditary coumarin resistance hyperlipemia,C0013604|C0439660|C0750384|C0020473|C0428465|C1717255,[patf]|[ftcn]|[dsyn]|[dsyn]|[fndg]|[clna],Edema|Hereditary|Coumarin Resistance|Hyperlipidemia|Serum lipids high (finding)|Edema:Finding:Point in time:^Patient:Ordinal,,,
edemahereditary coumarin resistancehyperlipemia,C0010206,"[orch, phsu]",coumarin,,,
n,C0369718|C0441922,"[aapp, imft]|[inpr]",N not otherwise specified Antibody|N+ (tumor staging),,,
serum TBG concentration,C0683149|C3814864|C1420598|C0004268|C0086045|C1446561,[qnco]|[gngm]|[gngm]|[menp]|[menp]|[qnco],serum concentration|SERPINA7 wt Allele|SERPINA7 gene|Attention|Mental concentration|Concentration measurement,,,